JP2006512413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512413A5 JP2006512413A5 JP2005502554A JP2005502554A JP2006512413A5 JP 2006512413 A5 JP2006512413 A5 JP 2006512413A5 JP 2005502554 A JP2005502554 A JP 2005502554A JP 2005502554 A JP2005502554 A JP 2005502554A JP 2006512413 A5 JP2006512413 A5 JP 2006512413A5
- Authority
- JP
- Japan
- Prior art keywords
- types
- group
- hpv
- use according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 10
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 231100000590 oncogenic Toxicity 0.000 claims 3
- 230000002246 oncogenic effect Effects 0.000 claims 3
- 239000000902 placebo Substances 0.000 claims 3
- 229940068196 placebo Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43503502P | 2002-12-20 | 2002-12-20 | |
| US60/435,035 | 2002-12-20 | ||
| US49665303P | 2003-08-20 | 2003-08-20 | |
| US60/496,653 | 2003-08-20 | ||
| PCT/EP2003/014562 WO2004056389A1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006512413A JP2006512413A (ja) | 2006-04-13 |
| JP2006512413A5 true JP2006512413A5 (enExample) | 2007-01-25 |
| JP5475939B2 JP5475939B2 (ja) | 2014-04-16 |
Family
ID=32685362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502554A Expired - Lifetime JP5475939B2 (ja) | 2002-12-20 | 2003-12-18 | Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20060251676A1 (enExample) |
| EP (1) | EP1572233B1 (enExample) |
| JP (1) | JP5475939B2 (enExample) |
| KR (3) | KR101361769B1 (enExample) |
| AP (1) | AP2005003347A0 (enExample) |
| AR (1) | AR042530A1 (enExample) |
| AT (1) | ATE503492T1 (enExample) |
| AU (1) | AU2003293942B2 (enExample) |
| BE (3) | BE2015C068I2 (enExample) |
| BR (1) | BR0317544A (enExample) |
| CA (1) | CA2510457C (enExample) |
| CY (1) | CY1111552T1 (enExample) |
| DE (1) | DE60336581D1 (enExample) |
| DK (1) | DK1572233T3 (enExample) |
| EA (2) | EA009179B1 (enExample) |
| EC (1) | ECSP055869A (enExample) |
| IL (1) | IL169085A (enExample) |
| IS (1) | IS2811B (enExample) |
| MA (1) | MA27581A1 (enExample) |
| MX (1) | MXPA05006764A (enExample) |
| MY (1) | MY144492A (enExample) |
| NO (1) | NO20052846L (enExample) |
| NZ (1) | NZ540811A (enExample) |
| OA (1) | OA13147A (enExample) |
| PL (1) | PL215257B1 (enExample) |
| PT (1) | PT1572233E (enExample) |
| TW (1) | TWI349557B (enExample) |
| WO (1) | WO2004056389A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU750587B2 (en) * | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| PE20060434A1 (es) * | 2004-06-16 | 2006-06-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| SG159529A1 (en) * | 2005-04-26 | 2010-03-30 | Glaxosmithkline Biolog Sa | Vaccine |
| DK2147926T3 (en) | 2007-04-29 | 2016-11-28 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated human papillomavirus type 18 L1 protein |
| US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
| WO2010099580A1 (en) * | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Treatment of infection |
| MX2011013566A (es) | 2009-06-19 | 2012-06-28 | Eyegene Inc | Vacunas para cancer cervical. |
| CA2938165A1 (en) | 2014-01-31 | 2015-08-06 | Ulisse Biomed S.R.L. | Biosensor for the determination of infections and associated pathologies |
| JP6663438B2 (ja) | 2014-10-24 | 2020-03-11 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | 癌および皮膚病変の治療 |
| US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
| RU2721417C2 (ru) * | 2015-06-02 | 2020-05-19 | Терумо Кабусики Кайся | Адъювантная композиция, содержащая алюминий, и содержащая ее вакцинная композиция |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| US12404306B2 (en) * | 2018-03-06 | 2025-09-02 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| EP3812395A4 (en) * | 2018-06-04 | 2022-03-30 | Xiamen University | MUTANT OF HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4332596A1 (de) * | 1993-09-24 | 1995-03-30 | Martin Josef Dr Sapp | Monoklonale Antikörper |
| CA2302545C (en) | 1997-09-05 | 2012-04-03 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps) |
| KR20010093290A (ko) * | 1999-02-05 | 2001-10-27 | 폴락 돈나 엘. | 사람 파필로마바이러스 백신 제제 |
| US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| IL153474A0 (en) * | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
-
2003
- 2003-12-18 KR KR1020127027784A patent/KR101361769B1/ko not_active Expired - Lifetime
- 2003-12-18 KR KR1020127026719A patent/KR20120118087A/ko not_active Withdrawn
- 2003-12-18 MY MYPI20034868A patent/MY144492A/en unknown
- 2003-12-18 AT AT03789346T patent/ATE503492T1/de active
- 2003-12-18 TW TW092135963A patent/TWI349557B/zh not_active IP Right Cessation
- 2003-12-18 US US10/540,099 patent/US20060251676A1/en not_active Abandoned
- 2003-12-18 JP JP2005502554A patent/JP5475939B2/ja not_active Expired - Lifetime
- 2003-12-18 OA OA1200500189A patent/OA13147A/en unknown
- 2003-12-18 EA EA200500834A patent/EA009179B1/ru not_active IP Right Cessation
- 2003-12-18 EA EA200701633A patent/EA200701633A1/ru unknown
- 2003-12-18 PL PL377710A patent/PL215257B1/pl unknown
- 2003-12-18 WO PCT/EP2003/014562 patent/WO2004056389A1/en not_active Ceased
- 2003-12-18 NZ NZ540811A patent/NZ540811A/en not_active IP Right Cessation
- 2003-12-18 KR KR1020057011497A patent/KR20050086924A/ko not_active Ceased
- 2003-12-18 AR ARP030104709A patent/AR042530A1/es unknown
- 2003-12-18 MX MXPA05006764A patent/MXPA05006764A/es active IP Right Grant
- 2003-12-18 DK DK03789346.8T patent/DK1572233T3/da active
- 2003-12-18 CA CA2510457A patent/CA2510457C/en not_active Expired - Lifetime
- 2003-12-18 BR BR0317544-8A patent/BR0317544A/pt not_active Application Discontinuation
- 2003-12-18 PT PT03789346T patent/PT1572233E/pt unknown
- 2003-12-18 EP EP03789346A patent/EP1572233B1/en not_active Expired - Lifetime
- 2003-12-18 AP AP2005003347A patent/AP2005003347A0/xx unknown
- 2003-12-18 AU AU2003293942A patent/AU2003293942B2/en not_active Expired
- 2003-12-18 DE DE60336581T patent/DE60336581D1/de not_active Expired - Lifetime
-
2005
- 2005-04-26 US US11/114,301 patent/US20050287161A1/en not_active Abandoned
- 2005-06-09 IS IS7885A patent/IS2811B/is unknown
- 2005-06-09 IL IL169085A patent/IL169085A/en active IP Right Grant
- 2005-06-13 NO NO20052846A patent/NO20052846L/no not_active Application Discontinuation
- 2005-06-20 EC EC2005005869A patent/ECSP055869A/es unknown
- 2005-07-18 MA MA28398A patent/MA27581A1/fr unknown
-
2011
- 2011-06-08 CY CY20111100549T patent/CY1111552T1/el unknown
-
2015
- 2015-12-09 BE BE2015C068C patent/BE2015C068I2/fr unknown
- 2015-12-09 BE BE2015C067C patent/BE2015C067I2/fr unknown
- 2015-12-09 BE BE2015C069C patent/BE2015C069I2/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lowy et al. | Prophylactic human papillomavirus vaccines | |
| Yousefi et al. | An update on human papilloma virus vaccines: history, types, protection, and efficacy | |
| EP1410805B1 (en) | Vaccine against HPV | |
| CA2510457A1 (en) | Hpv-16 and -18 l1 vlp vaccine | |
| Gambhira et al. | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 | |
| JP6029631B2 (ja) | ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法 | |
| US10046026B2 (en) | Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines | |
| JP2008534467A5 (enExample) | ||
| Schwarz et al. | Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature | |
| US20120177684A1 (en) | Papillomavirus vaccine compositions | |
| Wu et al. | Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach | |
| Kalnin et al. | Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes | |
| Roden et al. | The impact of preventive HPV vaccination | |
| JP2008539184A5 (enExample) | ||
| JP2013540421A5 (enExample) | ||
| JP2002532434A5 (enExample) | ||
| Ramet et al. | Position paper—HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians | |
| HRP20120930T1 (hr) | Cjepivo protiv hpv16 i hpv18 i još najmanje jednog tipa hpv, kojeg se bira između hpv31, 45 ili 52 | |
| Sultana | Human Papilloma Virus Vaccine for Cervical Cancer Prevention | |
| JP2008539182A5 (enExample) | ||
| TW202313658A (zh) | Hpv疫苗 | |
| CN101116745B (zh) | 人乳头瘤病毒的病毒样颗粒疫苗 | |
| Shah et al. | Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention | |
| Takehara et al. | Human Papillomavirus Vaccine: Its Application and Perspective | |
| Somasundaram | HPV vaccine: End to women's major health problem? |